Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Reports Q4 and Full-Year 2025 Financial Results
Summary
Thermo Fisher Scientific reported its financial results for Q4 and the full year 2025, showing a 7% increase in Q4 revenue to $12.21 billion and a 9% increase in Q4 GAAP diluted EPS to $5.21. Full-year revenue grew 4% to $44.56 billion, with a 7% increase in GAAP diluted EPS to $17.74. The company highlighted its operational performance, product launches, and capital deployment strategies as key drivers of its financial results.
Profitelligence Alerts
Get alerts for TMO
Be first to know when Thermo Fisher Scientific Inc. files with the SEC.
Filing Categories
Advertisement
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Official SEC Documents
Advertisement